TITLE:
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

CONDITION:
Myelodysplastic Syndrome

INTERVENTION:
CC-1088

SUMMARY:

      The primary objective of the study is to assess the safety of CC-1088 to patients with
      myelodysplastic syndromes (MDS).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        -  Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not
             therapy related.

          -  Patient must be able to adhere to the study visit schedule and other protocol
             requirements.

          -  Patient must understand and voluntarily sign an informed consent document.

          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test.

          -  Women must not be pregnant or lactating.
      
